MX338489B - Derivados de hidantoina utiles como inhibidores de kv3. - Google Patents

Derivados de hidantoina utiles como inhibidores de kv3.

Info

Publication number
MX338489B
MX338489B MX2013006343A MX2013006343A MX338489B MX 338489 B MX338489 B MX 338489B MX 2013006343 A MX2013006343 A MX 2013006343A MX 2013006343 A MX2013006343 A MX 2013006343A MX 338489 B MX338489 B MX 338489B
Authority
MX
Mexico
Prior art keywords
inhibitors
derivatives useful
hydantoin derivatives
hydantoin
compounds
Prior art date
Application number
MX2013006343A
Other languages
English (en)
Other versions
MX2013006343A (es
Inventor
Giuseppe Alvaro
Charles Large
Agostino Marasco
Anne Decor
Paolo Dambruoso
Simona Tommasi
Original Assignee
Autifony Therapeuticts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/068946 external-priority patent/WO2011069951A1/en
Priority claimed from GBGB1020607.6A external-priority patent/GB201020607D0/en
Priority claimed from GBGB1109508.0A external-priority patent/GB201109508D0/en
Priority claimed from GBGB1113757.7A external-priority patent/GB201113757D0/en
Application filed by Autifony Therapeuticts Ltd filed Critical Autifony Therapeuticts Ltd
Publication of MX2013006343A publication Critical patent/MX2013006343A/es
Publication of MX338489B publication Critical patent/MX338489B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos de fórmula (I): (Ver Formula) dichos compuestos son inhibidores de canales Kv3 y de uso en la profilaxis o el tratamiento de trastornos relacionados.
MX2013006343A 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3. MX338489B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2010/068946 WO2011069951A1 (en) 2009-12-11 2010-12-06 Imidazolidinedione derivatives
GBGB1020607.6A GB201020607D0 (en) 2010-12-06 2010-12-06 Novel compounds
GBGB1109508.0A GB201109508D0 (en) 2011-06-07 2011-06-07 Novel compounds
GBGB1113757.7A GB201113757D0 (en) 2011-08-10 2011-08-10 Novel compounds
PCT/GB2011/052414 WO2012076877A1 (en) 2010-12-06 2011-12-06 Hydantoin derivatives useful as kv3 inhibitors

Publications (2)

Publication Number Publication Date
MX2013006343A MX2013006343A (es) 2013-09-13
MX338489B true MX338489B (es) 2016-04-18

Family

ID=45464001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006343A MX338489B (es) 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3.

Country Status (18)

Country Link
US (13) US9346790B2 (es)
EP (1) EP2649066B1 (es)
JP (2) JP5913357B2 (es)
KR (1) KR101862375B1 (es)
CN (1) CN103328467B (es)
AU (1) AU2011340258C1 (es)
BR (1) BR112013013914B1 (es)
CA (1) CA2817205C (es)
DK (1) DK2649066T3 (es)
EA (2) EA023768B1 (es)
ES (1) ES2560304T3 (es)
HK (1) HK1190395A1 (es)
IL (3) IL226256A0 (es)
MX (1) MX338489B (es)
PL (1) PL2649066T3 (es)
SG (2) SG190203A1 (es)
WO (1) WO2012076877A1 (es)
ZA (1) ZA201403529B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010330048B9 (en) 2009-12-11 2015-02-19 Autifony Therapeutics Limited Imidazolidinedione derivatives
CA2817205C (en) 2010-12-06 2020-04-07 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
ES2576628T3 (es) * 2011-12-06 2016-07-08 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
BR112014028718A2 (pt) * 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
US9416115B2 (en) * 2013-12-20 2016-08-16 Gilead Scineces, Inc. Fused heterocyclic compounds as ion channel modulators
CN105916849B (zh) 2014-01-16 2020-07-07 Fmc公司 作为除草剂的嘧啶氧基苯衍生物
EP3120140B1 (en) * 2014-03-21 2018-10-31 Biotage AB Method and apparatus for the equilibration of a packed chromatography column
CN103980205B (zh) * 2014-06-05 2016-01-20 武汉格罗宁根医药科技有限公司 N-3-取代磺酰胺乙基-5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用
TWI713530B (zh) 2015-06-05 2020-12-21 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
RU2019138586A (ru) * 2017-05-02 2021-05-28 Фмк Корпорейшн Пиримидинилоксибензо-конденсированные соединения в качестве гербицидов
WO2018220762A1 (ja) 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
CN107556262B (zh) * 2017-08-14 2020-05-22 四川大学 一种2-取代基芳并噁唑的制备方法
DE112018007799T5 (de) 2018-07-03 2021-03-25 Cummins Emission Solutions Inc. Zersetzungsreaktor mit körpermischung
JP7465868B2 (ja) * 2018-10-16 2024-04-11 アウトイフオンイ トヘラペウトイクス リミテッド 新規化合物
US20210276985A1 (en) * 2018-10-16 2021-09-09 Autifony Therapeutics Limited Novel compounds
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation
US20220112176A1 (en) * 2019-03-25 2022-04-14 Bionomics Limited Substituted-n-heteroaryl compounds and uses thereof
JP7522203B2 (ja) 2020-02-06 2024-07-24 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３モジュレーター
US11638606B2 (en) 2020-04-15 2023-05-02 Bard Peripheral Vascular, Inc. Bipolar electrosurgical pleura sealing device, system, and method of operating same
EP3901152A1 (en) 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
CN112213428A (zh) * 2020-10-13 2021-01-12 辽宁科技大学 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
WO2023017263A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
WO2023101418A1 (ko) * 2021-12-03 2023-06-08 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474170A (en) * 1964-01-23 1969-10-21 Fmc Corp Pesticidal carbamates of dihydrobenzofuranols
US4143055A (en) * 1978-03-27 1979-03-06 Gruppo Lepetit S.P.A. 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) * 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
CA2007830A1 (en) * 1989-01-18 1990-07-18 Shuji Ozawa 2,3-dihydro-3, 3-dimethyl-5-trifluoromethanesulfonyloxy-benzofurans, process for producing them and herbicides containing them
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
JPH03153606A (ja) * 1989-11-10 1991-07-01 Mitsui Petrochem Ind Ltd 除草剤組成物
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
JPH11505546A (ja) 1995-05-17 1999-05-21 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性の環式アミド類
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
PL324291A1 (en) 1995-06-20 1998-05-11 Du Pont Anthropodicidal and fungicidal cyclic amides
EP0934283A2 (en) 1996-08-01 1999-08-11 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
JP2001506984A (ja) 1996-11-26 2001-05-29 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー メチル置換された殺菌・殺カビ剤および殺節足動物剤
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
WO1998033382A1 (en) 1997-01-30 1998-08-06 E.I. Du Pont De Nemours And Company Fungicidal compositions
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
WO2001007032A1 (fr) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Inhibiteurs de differenciation th2
MXPA02009763A (es) 2000-04-04 2003-03-27 Shionogi & Co Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa.
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
AU2002354410A1 (en) 2001-12-05 2003-06-17 Japan Tobacco Inc. Triazole compound and medicinal use thereof
ES2311711T3 (es) 2002-02-07 2009-02-16 The Curators Of The University Of Missouri Compuestos de 4-(3-hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos como receptores de opioides.
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ATE541571T1 (de) 2005-05-13 2012-02-15 Univ California Diarylhydantoin-verbindung
PT2656841T (pt) 2006-03-27 2016-09-28 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
KR101600230B1 (ko) 2006-03-29 2016-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
BRPI0807717A2 (pt) 2007-04-20 2014-05-20 Deciphera Pharmaceuticals Llc Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
EP2252592A1 (de) 2008-02-07 2010-11-24 Sanofi-Aventis Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
AU2009289846B2 (en) * 2008-09-02 2014-10-16 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
US8178547B2 (en) * 2008-12-22 2012-05-15 Roche Palo Alto Llc Heterocyclic antiviral compounds
AU2010330048B9 (en) * 2009-12-11 2015-02-19 Autifony Therapeutics Limited Imidazolidinedione derivatives
CN102652134A (zh) 2009-12-14 2012-08-29 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
CA2817205C (en) * 2010-12-06 2020-04-07 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
JP2018533579A (ja) 2015-10-30 2018-11-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 高分子量かつ密な被覆を有する粘液浸透粒子

Also Published As

Publication number Publication date
JP2016145215A (ja) 2016-08-12
PL2649066T3 (pl) 2017-04-28
EP2649066A1 (en) 2013-10-16
US10098881B2 (en) 2018-10-16
US10835534B2 (en) 2020-11-17
SG190203A1 (en) 2013-06-28
US20150336936A1 (en) 2015-11-26
BR112013013914B1 (pt) 2021-10-26
US10265316B2 (en) 2019-04-23
CA2817205C (en) 2020-04-07
US20140323508A1 (en) 2014-10-30
US9133175B2 (en) 2015-09-15
EA023768B1 (ru) 2016-07-29
AU2011340258A1 (en) 2013-05-30
EA027532B1 (ru) 2017-08-31
US20200179385A1 (en) 2020-06-11
US9833452B2 (en) 2017-12-05
BR112013013914A2 (pt) 2016-09-13
US11583527B2 (en) 2023-02-21
EA201390609A1 (ru) 2014-01-30
US20170273981A1 (en) 2017-09-28
US11197859B2 (en) 2021-12-14
US9422272B2 (en) 2016-08-23
JP2013544873A (ja) 2013-12-19
IL253102A0 (en) 2017-08-31
AU2011340258C1 (en) 2016-10-20
CN103328467B (zh) 2016-08-10
SG11201402529RA (en) 2014-06-27
CN103328467A (zh) 2013-09-25
US20160251340A1 (en) 2016-09-01
US11541052B2 (en) 2023-01-03
EP2649066B1 (en) 2015-10-21
JP6118927B2 (ja) 2017-04-19
US20180036308A1 (en) 2018-02-08
HK1190395A1 (en) 2014-07-04
US20160317537A1 (en) 2016-11-03
WO2012076877A1 (en) 2012-06-14
MX2013006343A (es) 2013-09-13
IL253102B (en) 2018-04-30
ES2560304T3 (es) 2016-02-18
KR20130138815A (ko) 2013-12-19
US20130267510A1 (en) 2013-10-10
ZA201403529B (en) 2020-03-25
US20220054490A1 (en) 2022-02-24
US20190192516A1 (en) 2019-06-27
US20200360379A1 (en) 2020-11-19
DK2649066T3 (en) 2016-01-11
US20210023084A1 (en) 2021-01-28
CA2817205A1 (en) 2012-06-14
IL253104A0 (en) 2017-08-31
EA201490922A1 (ru) 2015-03-31
JP5913357B2 (ja) 2016-04-27
US20190000849A1 (en) 2019-01-03
IL226256A0 (en) 2013-07-31
US10555945B2 (en) 2020-02-11
KR101862375B1 (ko) 2018-05-29
US9346790B2 (en) 2016-05-24
AU2011340258B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
IN2015DN01156A (es)
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
JO2892B1 (en) CYP inhibitors 17
MY181898A (en) Heterocyclic compounds and uses thereof
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
TN2011000673A1 (en) Bace inhibitors
UA105911C2 (uk) Сульфонамідні похідні
EA201170832A1 (ru) Пуриновые соединения
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IN2012DN00692A (es)
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
MX2012004780A (es) Inhibidores de akt.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2012001620A (es) Derivados de n1-acil-5-fluoropirimidinona.
CA2887539C (en) Azaquinazoline carboxamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration